Establishing laboratory reference ranges for adults and children in Kilifi, Kenya
Downs LO. et al, (2024)
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.
Kiguli S. et al, (2024), EClinicalMedicine, 72
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS. et al, (2024), Lancet, 403, 533 - 544
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).
Maitland K. et al, (2024), Wellcome Open Res, 9
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
[A global core outcome measurement set for snakebite clinical trials].
Abouyannis M. et al, (2023), Med Trop Sante Int, 3
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi D. et al, (2023), Lancet Infect Dis, 23, 974 - 982
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Sci Transl Med, 15
A global core outcome measurement set for snakebite clinical trials.
Abouyannis M. et al, (2023), Lancet Glob Health, 11, e296 - e300
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome open research, 8
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome Open Res, 8
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).
Maitland K. et al, (2023), Wellcome Open Res, 8
Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial
Wamae K. et al, (2022), Wellcome Open Research, 7, 95 - 95
A pragmatic randomized controlled trial of standard care versus steroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)
Lucinde R. et al, (2022), Wellcome Open Research, 7, 269 - 269
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
van der Pluijm RW. et al, (2022), Lancet Infect Dis, 22, 765 - 766